Outcomes in patients with poorly differentiated thyroid carcinoma

Area of Science:

• Endocrinology
• Oncology
• Surgical Oncology

Background:

• Poorly differentiated thyroid cancer (PDTC) is a rare subtype, comprising 1-15% of all thyroid malignancies.
• This study focuses on outcomes in a substantial cohort of PDTC patients treated at a specialized cancer center.

Purpose of the Study:

• To evaluate the treatment outcomes for patients with poorly differentiated thyroid cancer.
• To identify prognostic factors influencing disease-specific survival in PDTC.

Main Methods:

• Retrospective analysis of 91 primary PDTC patients treated between 1986 and 2009.
• Kaplan-Meier method for survival analysis; Chi-squared test for characteristic comparison.
• Univariate and multivariate analyses (log-rank, Cox proportional hazards) to identify predictors of disease-specific survival (DSS).

Main Results:

• Median follow-up was 50 months; 5-year overall survival was 62%, and DSS was 66%.
• 5-year locoregional control was 81%, while distant control was 59%.
• Advanced pathological T stage (pT4a) and distant metastasis (M1) were independent predictors of worse DSS.

Conclusions:

• Effective locoregional control is achievable in PDTC with surgery and adjuvant therapy.
• Distant metastases are the predominant cause of PDTC mortality, underscoring the challenge of systemic disease control.